Siplizumab
CAS No. 288392-69-8
Siplizumab( —— )
Catalog No. M36839 CAS No. 288392-69-8
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 615 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSiplizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSiplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.
-
DescriptionSiplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches na ve and bona fide regulatory T cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number288392-69-8
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Binder C, et, al. Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro. Front Immunol. 2020 Nov 11;11:592553.?
molnova catalog
related products
-
Dimefuron
Dimefuron is a chemical compound from the group of phenylureas used as a herbicide or insecticide.
-
3,4,5-Tricaffeoylqui...
3,4,5-Tricaffeoylquinic acid may attenuate the TNF-α±- and LPS-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor 4 expression-mediated activation of the Akt, ERK and NF-κB pathways, it may exert an inhibitory effect against the pro-inflammatory mediator-induced skin disease.
-
ISOGINKGETIN
Isoginkgetin, a compound derived from the leaves of Ginkgo biloba, to up-regulate adiponectin secretion with potency comparable to that of rosiglitazone, a known modulator of adiponectin production.
Cart
sales@molnova.com